The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
Open accessAbstract
Given the increase in antibiotic-resistant bacteria, alongside the alarmingly low rate of newly approved antibiotics for clinical usage, we are on the verge of not having effective treatments for many common infectious diseases. Historically, antibiotic discovery has been crucial in outpacing resistance and success is closely related to systematic procedures—platforms—that have catalyzed the antibiotic golden age, namely the Waksman platform, followed by the platforms of semi-synthesis and fully synthetic antibiotics. Said platforms resulted in the major antibiotic classes: aminoglycosides, amphenicols, ansamycins, beta-lactams, lipopeptides, diaminopyrimidines, fosfomycins, imidazoles, macrolides, oxazolidinones, streptogramins, polymyxins, sulphonamides, glycopeptides, quinolones and tetracyclines. During the genomics era came the target-based platform, mostly considered a failure due to limitations in translating drugs to the clinic. Therefore, cell-based platforms were re-instituted, and are still of the utmost importance in the fight against infectious diseases. Although the antibiotic pipeline is still lackluster, especially of new classes and novel mechanisms of action, in the post-genomic era, there is an increasingly large set of information available on microbial metabolism. The translation of such knowledge into novel platforms will hopefully result in the discovery of new and better therapeutics, which can sway the war on infectious diseases back in our favor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30605-4 · Cited by 2,945
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Difference gel electrophoresis. A single gel method for detecting changes in protein extracts
Ünlü, M., Morgan, M. E., & Minden, J. S. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150181133 · Cited by 2,179
A brief history of the antibiotic era: lessons learned and challenges for the future
Aminov, R. I. (2010) · Frontiers in Microbiology · doi:10.3389/fmicb.2010.00134 · Cited by 1,628
Access to effective antimicrobials: a worldwide challenge
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00474-2 · Cited by 1,465
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Frieri, M., Kumar, K., & Boutin, A. (2017) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.08.007 · Cited by 1,100
Human commensals producing a novel antibiotic impair pathogen colonization
Zipperer, A., Konnerth, M. C., Laux, C., Berscheid, A., Janek, D., Weidenmaier, C., Burian, M., Schilling, N. A., Slavetinsky, C., Marschal, M., et al. (2016) · Nature · doi:10.1038/nature18634 · Cited by 938
Alternatives to antibiotics—a pipeline portfolio review
Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., Foster, S., Gilmore, B. F., Hancock, R. E. W., Harper, D., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00466-1 · Cited by 848
Use of Ichip for High-Throughput In Situ Cultivation of “Uncultivable” Microbial Species
Nichols, D., Cahoon, N., Trakhtenberg, E. M., Pham, L., Mehta, A., Belanger, A., Kanigan, T., Lewis, K., & Epstein, S. S. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.01754-09 · Cited by 732
Insights from 20 years of bacterial genome sequencing
Land, M., Hauser, L., Jun, S.-R., Nookaew, I., Leuze, M. R., Ahn, T.-H., Karpinets, T., Lund, O., Kora, G., Wassenaar, T., et al. (2015) · Functional & Integrative Genomics · doi:10.1007/s10142-015-0433-4 · Cited by 727
Donia, M. S., Cimermancic, P., Schulze, C. J., Wieland Brown, L. C., Martin, J., Mitreva, M., Clardy, J., Linington, R. G., & Fischbach, M. A. (2014) · Cell · doi:10.1016/j.cell.2014.08.032 · Cited by 705
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
ESKAPEing the labyrinth of antibacterial discovery
Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., & Miller, A. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4572 · Cited by 608
RifamycinMode of Action, Resistance, and Biosynthesis
Floss, H. G., & Yu, T.-W. (2005) · Chemical Reviews · doi:10.1021/cr030112j · Cited by 547
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
The history of the tetracyclines
Nelson, M. L., & Levy, S. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06354.x · Cited by 468
The antibiotic resistance crisis, with a focus on the United States
Martens, E., & Demain, A. L. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.30 · Cited by 445
The Evolving Role of Chemical Synthesis in Antibacterial Drug Discovery
Wright, P. M., Seiple, I. B., & Myers, A. G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310843 · Cited by 426
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
Swinney, D. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.236 · Cited by 413
Penicillin: its discovery and early development
Ligon, B. L. (2004) · Seminars in Pediatric Infectious Diseases · doi:10.1053/j.spid.2004.02.001 · Cited by 412
The natural history of antibiotics
Clardy, J., Fischbach, M. A., & Currie, C. R. (2009) · Current Biology · doi:10.1016/j.cub.2009.04.001 · Cited by 402
Self-medication and antibiotic resistance: Crisis, current challenges, and prevention
Rather, I. A., Kim, B.-C., Bajpai, V. K., & Park, Y.-H. (2017) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2017.01.004 · Cited by 379
Michalopoulos, A. S., Livaditis, I. G., & Gougoutas, V. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.07.007 · Cited by 378
Discovery, mechanisms of action and combination therapy of artemisinin
Cui, L., & Su, X.-Z. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.68 · Cited by 371
Transcriptomics in the RNA-seq era
McGettigan, P. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.12.008 · Cited by 358
A platform for the discovery of new macrolide antibiotics
Seiple, I. B., Zhang, Z., Jakubec, P., Langlois-Mercier, A., Wright, P. M., Hog, D. T., Yabu, K., Allu, S. R., Fukuzaki, T., Carlsen, P. N., et al. (2016) · Nature · doi:10.1038/nature17967 · Cited by 351
Antibiotics in the clinical pipeline at the end of 2015
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.72 · Cited by 349
Opportunities for natural products in 21st century antibiotic discovery
Wright, G. D. (2017) · Natural Product Reports · doi:10.1039/c7np00019g · Cited by 343
Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens
Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P., Gruss, A., & Poyart, C. (2009) · Nature · doi:10.1038/nature07772 · Cited by 317
Natural Products as a Source for Novel Antibiotics
Moloney, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.001 · Cited by 308
A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics
Charest, M. G., Lerner, C. D., Brubaker, J. D., Siegel, D. R., & Myers, A. G. (2005) · Science · doi:10.1126/science.1109755 · Cited by 298
The action mechanism of daptomycin
Taylor, S. D., & Palmer, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.052 · Cited by 298
History of antimicrobial drug discovery: Major classes and health impact
Aminov, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 296
Epidemiology of antimicrobial resistance in bloodstream infections
Akova, M. (2016) · Virulence · doi:10.1080/21505594.2016.1159366 · Cited by 292
Discovery research: the scientific challenge of finding new antibiotics
Livermore, D. M., on behalf of the British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, Blaser, M., Carrs, O., Cassell, G., Fishman, N., Guidos, R., Levy, S., Powers, J., Norrby, R., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr262 · Cited by 284
Studying bacterial transcriptomes using RNA-seq
Croucher, N. J., & Thomson, N. R. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.09.009 · Cited by 278
Recover the lost art of drug discovery
Lewis, K. (2012) · Nature · doi:10.1038/485439a · Cited by 276
Prediction of antibiotic resistance by gene expression profiles
Suzuki, S., Horinouchi, T., & Furusawa, C. (2014) · Nature Communications · doi:10.1038/ncomms6792 · Cited by 267
The Composition of Ehrlich's Salvarsan: Resolution of a Century‐Old Debate
Lloyd, N. C., Morgan, H. W., Nicholson, B. K., & Ronimus, R. S. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461471 · Cited by 256
Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”: Miniperspective
Bisacchi, G. S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501881c · Cited by 252
Antibiotics in late clinical development
Fernandes, P., & Martens, E. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.025 · Cited by 247
Empirical antibacterial drug discovery—Foundation in natural products
Singh, S. B., & Barrett, J. F. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.016 · Cited by 245
Renwick, M. J., Brogan, D. M., & Mossialos, E. (2016) · The Journal of Antibiotics · doi:10.1038/ja.2015.98 · Cited by 233
Can NMR solve some significant challenges in metabolomics?
Nagana Gowda, G. A., & Raftery, D. (2015) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2015.07.014 · Cited by 232
Outpatient antibiotic prescribing in the United States: 2000 to 2010
Lee, G. C., Reveles, K. R., Attridge, R. T., Lawson, K. A., Mansi, I. A., Lewis, J. S., & Frei, C. R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-96 · Cited by 231
Recent updates of carbapenem antibiotics
El-Gamal, M. I., Brahim, I., Hisham, N., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.022 · Cited by 214
What is an “ideal” antibiotic? Discovery challenges and path forward
Singh, S. B., Young, K., & Silver, L. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.003 · Cited by 201
Cell-based assays: fuelling drug discovery
Michelini, E., Cevenini, L., Mezzanotte, L., Coppa, A., & Roda, A. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3933-z · Cited by 197
Linezolid, the first oxazolidinone antibacterial agent
Leach, K. L., Brickner, S. J., Noe, M. C., & Miller, P. F. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05962.x · Cited by 195
Gilbert, I. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400362b · Cited by 190
Antibiotic resistance: A current epilogue
Dodds, D. R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.005 · Cited by 187
Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery
Lindon, J. C., & Nicholson, J. K. (2007) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2007.08.009 · Cited by 178
The Molecular Origins of Life: Assembling Pieces of the Puzzle
(1998) · Cambridge University Press eBooks · doi:10.1017/cbo9780511626180 · Cited by 174
Dersch, P., Khan, M. A., Mühlen, S., & Görke, B. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00803 · Cited by 172
Mining the Metabiome: Identifying Novel Natural Products from Microbial Communities
Milshteyn, A., Schneider, J. S., & Brady, S. F. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.006 · Cited by 171
A Common Platform for Antibiotic Dereplication and Adjuvant Discovery
Cox, G., Sieron, A. O., King, A. M., Pascale, G. D., Pawlowski, A. C., Koteva, K. K., & Wright, G. D. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.11.011 · Cited by 160
Accelerating resistance, inadequate antibacterial drug pipelines and international responses
Theuretzbacher, U. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.12.006 · Cited by 157
Prediction of Mechanisms of Action of Antibacterial Compounds by Gene Expression Profiling
Hutter, B., Schaab, C., Albrecht, S., Borgmann, M., Brunner, N. A., Freiberg, C., Ziegelbauer, K. B., Rock, C. O., Ivanov, I., & Loferer, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.2838-2844.2004 · Cited by 153
Daptomycin: From the Mountain to the Clinic, with Essential Help from Francis Tally, MD
Eisenstein, B. I., Oleson, F. B., & Baltz, R. H. (2010) · Clinical Infectious Diseases · doi:10.1086/647938 · Cited by 150
New approaches to antimicrobial discovery
Lewis, K. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.002 · Cited by 143
Metronidazole resistance and nim genes in anaerobes: A review
Alauzet, C., Lozniewski, A., & Marchandin, H. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.10.004 · Cited by 141
Lipidomics as a Principal Tool for Advancing Biomedical Research
Lam, S. M., & Shui, G. (2013) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2013.06.007 · Cited by 139
Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches
Lee, J. A., & Berg, E. L. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113506118 · Cited by 138
Roe, M. R., & Griffin, T. J. (2006) · PROTEOMICS · doi:10.1002/pmic.200500876 · Cited by 134
The introduction of ‘chemotherapy’ using arsphenamine – the first magic bullet
Williams, K. (2009) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2009.09k036 · Cited by 132
Characterization and prediction of the mechanism of action of antibiotics through NMR metabolomics
Hoerr, V., Duggan, G. E., Zbytnuik, L. D., Poon, K., Große, C., Neugebauer, U., Methling, K., Löffler, B., & Vogel, H. J. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0696-5 · Cited by 130
Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence β-lactams)
Bentley, R. (2009) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-009-0553-8 · Cited by 129
Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance
Brazas, M. D., & Hancock, R. E. W. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03566-x · Cited by 127
Kostyanev, T., Bonten, M. J. M., O'Brien, S., Steel, H. M., Ross, S., François, B., Tacconelli, E., Winterhalter, M., Stavenger, R. A., Karlén, A., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv339 · Cited by 126
A metabolic network approach for the identification and prioritization of antimicrobial drug targets
Chavali, A. K., D’Auria, K. M., Hewlett, E. L., Pearson, R. D., & Papin, J. A. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2011.12.004 · Cited by 125
Kolmeder, C. A., & de Vos, W. M. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.05.018 · Cited by 124
Bacterial fatty acid metabolism in modern antibiotic discovery
Yao, J., & Rock, C. O. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.09.014 · Cited by 122
Redesign of Glycopeptide Antibiotics: Back to the Future
James, R. C., Pierce, J. G., Okano, A., Xie, J. H., & Boger, D. L. (2012) · ACS Chemical Biology · doi:10.1021/cb300007j · Cited by 118
Using bacterial genomes and essential genes for the development of new antibiotics
Fields, F. R., Lee, S. W., & McConnell, M. J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.002 · Cited by 118
Streptogramins – Two are better than one!
Mast, Y., & Wohlleben, W. (2013) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2013.08.008 · Cited by 117
Protein phosphorylation in bacterial signal transduction
Kobir, A., Shi, L., Bošković, A., Grangeasse, C., Franjević, D., & Mijakovic̀, I. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.01.006 · Cited by 115
Proteome studies of bacterial antibiotic resistance mechanisms
Vranakis, I., Goniotakis, I., Psaroulaki, A., Sandalakis, V., Tselentis, Y., Gevaert, K., & Tsiotis, G. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.10.027 · Cited by 111
Postgenomic Strategies in Antibacterial Drug Discovery
Brötz‐Oesterhelt, H., & Saß, P. (2010) · Future Microbiology · doi:10.2217/fmb.10.119 · Cited by 105
Tyrosine phosphorylation and bacterial virulence
Whitmore, S. E., & Lamont, R. J. (2012) · International Journal of Oral Science · doi:10.1038/ijos.2012.6 · Cited by 104
Nosocomial or Hospital-acquired Infections: An Overview
McFee, R. B. (2009) · Disease-a-Month · doi:10.1016/j.disamonth.2009.03.014 · Cited by 102
Infection control through the ages
Smith, P. W., Watkins, K., & Hewlett, A. L. (2011) · American Journal of Infection Control · doi:10.1016/j.ajic.2011.02.019 · Cited by 100
Lipidomics from an analytical perspective
Sandra, K., & Sandra, P. J. F. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.06.010 · Cited by 100
Development of a platform for the discovery and practical synthesis of new tetracycline antibiotics
Liu, F., & Myers, A. G. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.03.011 · Cited by 100
Panel of Bacillus subtilis Reporter Strains Indicative of Various Modes of Action
Hutter, B., Fischer, C., Jacobi, A., Schaab, C., & Loferer, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2588-2594.2004 · Cited by 85
The impact of transcriptome and proteome analyses on antibiotic drug discovery
Freiberg, C., Brötz‐Oesterhelt, H., & Labischinski, H. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.08.010 · Cited by 83
New antibiotics from Nature’s chemical inventory
Wencewicz, T. A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.014 · Cited by 80
Biological atomism and cell theory
Nicholson, D. J. (2010) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2010.07.009 · Cited by 78
Mass-spectrometry-based microbial metabolomics: recent developments and applications
Gao, P., & Xu, G. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8127-7 · Cited by 77
Mathematical modeling in cancer drug discovery
Wang, Z., & Deisboeck, T. S. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.015 · Cited by 71
Genomics and transcriptomics in drug discovery
Dopazo, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.003 · Cited by 70
New approaches to antibiotic discovery
Kealey, C., Creaven, C. A., Murphy, C. D., & Brady, D. B. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2311-8 · Cited by 70
Cyphert, E. L., Wallat, J. D., Pokorski, J. K., et al. (2017) · Antibiotics · doi:10.3390/antibiotics6020011 · Cited by 69
Antibiotics from microbes: converging to kill
Fischbach, M. A. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.07.002 · Cited by 68
Mäder, U., Nicolas, P., Richard, H., Bessières, P., & Aymerich, S. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.10.003 · Cited by 68
Pioneers in infection control—Joseph Lister
Newsom, S. W. B. (2003) · Journal of Hospital Infection · doi:10.1016/j.jhin.2003.08.001 · Cited by 66
The application of next-generation sequencing technologies to drug discovery and development
Woollard, P. M., Mehta, N., Vamathevan, J. J., Horn, S. V., Bonde, B. K., & Dow, D. J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.03.006 · Cited by 65
Goodbye to brute force in antibiotic discovery?
Kolter, R., & van Wezel, G. P. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2015.20 · Cited by 64
New technologies accelerate the exploration of non-coding RNAs in horticultural plants
Liu, D., Mewalal, R., Hu, R., Tuskan, G. A., & Yang, X. (2017) · Horticulture Research · doi:10.1038/hortres.2017.31 · Cited by 64
When will the genomics investment pay off for antibacterial discovery?
Mills, S. D. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.11.025 · Cited by 58
Proteomic signatures in antibiotic research
Wenzel, M., & Bandow, J. E. (2011) · PROTEOMICS · doi:10.1002/pmic.201100046 · Cited by 57
Farrell, L., Lo, R., Wanford, J. J., Jenkins, A., Maxwell, A., & Piddock, L. J. V. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky208 · Cited by 49
Gonçalves-Carneiro, D., Clarke, T. L., Davies, C. C., & Bailey, D. (2015) · Methods · doi:10.1016/j.ymeth.2015.08.022 · Cited by 39
Identifying targets for antibiotic development using omics technologies
Pulido, M. R., García‐Quintanilla, M., Gil-Marqués, M. L., & McConnell, M. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.11.014 · Cited by 39
Sales, K. C., Rosa, F., Sampaio, P., Fonseca, L. P., Lopes, M. B., & Calado, C. R. C. (2015) · Applied Spectroscopy · doi:10.1366/14-07588 · Cited by 39
Self-citationPhosphoproteomics in drug discovery
Morris, M. K., Chi, A., Melas, I. N., & Alexopoulos, L. G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.010 · Cited by 38
Pipeline of Known Chemical Classes of Antibiotics
Mendes, C. D. D. S., & Antunes, A. M. D. S. (2013) · Antibiotics · doi:10.3390/antibiotics2040500 · Cited by 37
The comeback of trimethoprim in France
Caron, F., Wehrle, V., & Etienne, M. (2017) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2016.12.001 · Cited by 31
Vihervaara, T., Suoniemi, M., & Laaksonen, R. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.008 · Cited by 24
Fu, H., Hu, X., Li, C., Li, Y., Wang, Y., Jiang, J., Bi, C., Tang, S., You, X., & Song, D. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.024 · Cited by 24
Deng, S., Ma, X., Su, E., & Wei, D. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.12.034 · Cited by 19
Recent Progress on the Development of Novel Antitubercular Agents from Whole-Cell Screening Hits
Yokokawa, F. (2014) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.72.1239 · Cited by 6
New Drugs and Emerging Leads in Antibacterial Drug Discovery
Brown, D. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12409-6 · Cited by 6
Cited by
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Metal organic framework-based antibacterial agents and their underlying mechanisms
Han, D., Liu, X., & Wu, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00460g · Cited by 349
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Inhibitors of bacterial H 2 S biogenesis targeting antibiotic resistance and tolerance
Shatalin, K., Nuthanakanti, A., Kaushik, A., Shishov, D., Peselis, A., Shamovsky, I., Pani, B., Lechpammer, M., Vasilyev, N., Shatalina, E., et al. (2021) · Science · doi:10.1126/science.abd8377 · Cited by 259
Metadata
- Authors
- Ribeiro da Cunha, B., Fonseca, L. P., & Calado, C. R. C.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2019-04-24
- Volume
- 8
- Issue
- 2
- Pages
- 45
- ISSN
- 2079-6382 (ISSN-L)
- OpenAlex
- W2941444136
- Cited by
- 353
- References
- 117
- FWCI
- 20.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.